Anemia

Ferric Citrate Controls Phosphorus, Cuts ESA Use

Ferric Citrate Controls Phosphorus, Cuts ESA Use

By

Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.

ESA Use May Lower Risk of Transfusion

ESA Use May Lower Risk of Transfusion

By

Benefit seen among anemia and hemodialysis patients with hemoglobin levels below 10 g/dL.

Earlier Use of ESAs Benefits Non-Dialysis Kidney Disease (CKD) Patients

Earlier Use of ESAs Benefits Non-Dialysis Kidney Disease (CKD) Patients

By

Renal events are significantly less likely if erythropoiesis-stimulating agents are started at hemoglobin levels below 11 g/dL.

Giving Vitamin B6 Ups Resistance to ESAs

Giving Vitamin B6 Ups Resistance to ESAs

By

New finding on vitamin B6 is the opposite of what investigators hypothesized on patients with anemia.

Data Challenge IV Iron Withholding Guideline

Data Challenge IV Iron Withholding Guideline

By

IV iron in anemia hemodialysis patients hospitalized for bacterial infections found not to worsen outcomes.

Anemia Management Practices Shift, Study Finds

Anemia Management Practices Shift, Study Finds

By

Use of erythropoiesis-stimulating agents in anemia patients decreased, while use of iron increased.

Prolonged Bleeding Times Linked to Severe Anemia in Chronic Kidney Disease (CKD)

Prolonged Bleeding Times Linked to Severe Anemia in Chronic Kidney Disease (CKD)

By

Hemoglobin level below 8 mg/dL associated with 82% increased odds of prolonged bleeding time with anemia.

Anemia Found to Affect Renal Recovery from Acute Kidney Injury (AKI)

Anemia Found to Affect Renal Recovery from Acute Kidney Injury (AKI)

By

Highest quintile of hemoglobin associated with 6-fold increased odds of complete or partial recovery of anemia in acute kidney injury (AKI).

Alternate Night Home Hemodialysis Improves Anemia

Alternate Night Home Hemodialysis Improves Anemia

By

Researchers believe nocturnal home hemodialysis (NHHD) performed every other night may be superior to NHHD performed 6 or 7 times a week.

Body Fat May Improve Anemia Drug Response

Body Fat May Improve Anemia Drug Response

By

Hemodialysis patients with a higher percentage of fat tissue respond better to erythropoiesis-stimulating agents.

Pre-Surgery Anemia Ups CKD Patients' Risks

Pre-Surgery Anemia Ups CKD Patients' Risks

By

Low hemoglobin levels increase the risk of death, sepsis, and cerebrovascular accidents following cardiac surgery.

ESA Use in Dialysis Patients May Increase Their Cancer Risk

ESA Use in Dialysis Patients May Increase Their Cancer Risk

By

Doses higher than 70 μg per week were associated with a 77% greater risk of cancer compared with non-use of the agents.

Ascorbic Acid Found to Reduce Darbepoetin Requirement

Ascorbic Acid Found to Reduce Darbepoetin Requirement

By

It also was associated with high hemoglobin levels and reduced levels of C-reactive protein.

Value of ESAs in Avoiding Transfusion Questionable

Value of ESAs in Avoiding Transfusion Questionable

By

In 3 trials, the annual cost for preventing 1 patient from being transfused varied from $61,188 to $317,988.

Anemia Management Changing in Peritoneal Dialysis Patients

Anemia Management Changing in Peritoneal Dialysis Patients

By

Study reveals a decline in the use of erythropoiesis-stimulating agents and an increase in the use of iron.

High Phosphorus Ups Anemia Risk in the Non-CKD Population

High Phosphorus Ups Anemia Risk in the Non-CKD Population

By

Each 0.5 mg/dL increment in phosphorus was associated with a 7% increased risk of anemia.

Inappropriate ESA Use Reduced by Pharmacy Protocol

Inappropriate ESA Use Reduced by Pharmacy Protocol

By

Ordering process cut the number of epoetin alfa doses by 71% and medication costs by 69%.

Safety Profiles of IV Iron Products Compared

Safety Profiles of IV Iron Products Compared

By

In a head-to-head comparison, researchers observed a higher rate of adverse events with iron dextran than iron sucrose or ferric gluconate.

Phosphate Binder May Eliminate Need for IV Iron

Phosphate Binder May Eliminate Need for IV Iron

By

Iron absorbed from oral ferric citrate boosted iron stores and sustained hemoglobin levels.

CMV in Kidney Disease Linked with Anemia

CMV in Kidney Disease Linked with Anemia

Patients with higher levels of anti-CMV antibodies have lower number of red blood cells.

Renal Stenting and the CORAL Study: Interview with Lance Dworkin, MD

Renal Stenting and the CORAL Study: Interview with Lance Dworkin, MD

By

CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.

ESA Resistance Found To Increase Mortality

By

Greater resistance to ESA is associated with an increased risk of death among patients on chronic HD.

MI-Acquired Anemia Rates Vary by Hospital

MI-Acquired Anemia Rates Vary by Hospital

Considerable variation in incidence of HAA across hospitals; teaching status and region linked to risk.

Ribavirin May Treat HEV Infection in Transplant Recipients

Ribavirin May Treat HEV Infection in Transplant Recipients

By

Serum hepatitis E virus levels were undetectable in 78% of patients at least 6 months after stopping treatment.

IV Iron Drugs Demonstrate Similar Efficacy, AE Rates

By

Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.

Low Iron Tied to Higher Stroke Risk

Low Iron Tied to Higher Stroke Risk

Platelets may aggregate more easily in iron-deficient patients.

Novel Iron Compound Patented in Japan

Novel Iron Compound Patented in Japan

By

Soluble ferric pyrophosphate (Triferic), an investigational drug, is delivered to hemodialysis patients via dialysate.

Guidelines and the Older Patient with CKD

Guidelines and the Older Patient with CKD

By By

Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.

IV Iron Drugs Demonstrate Similar Efficacy, Safety in CKD Patients

IV Iron Drugs Demonstrate Similar Efficacy, Safety in CKD Patients

By

In a study, ferumoxytol and iron sucrose treatment was associated with comparable increases in hemoglobin levels and adverse event rates.

Sickle Cell Trait May Raise Need for Anemia Meds in Dialysis Patients

Sickle Cell Trait May Raise Need for Anemia Meds in Dialysis Patients

By

This trait in African-American hemodialysis patients was associated with a 13.2% higher dose of erythropoiesis-stimulating agents.

Sign Up for Free e-newsletters